Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Articles

Page Path
HOME > Intest Res > Volume 13(3); 2015 > Article
Review Tacrolimus for the Treatment of Ulcerative Colitis
Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe
Intestinal Research 2015;13(3):219-226.
DOI: https://doi.org/10.5217/ir.2015.13.3.219
Published online: June 9, 2015

Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

Correspondence to Mamoru Watanabe, Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Tel: +81-3-5803-5877, Fax: +81-3-5803-0268, mamoru.gast@tmd.ac.jp
• Received: May 4, 2014   • Revised: May 6, 2014   • Accepted: May 6, 2014

© Copyright 2015. Korean Association for the Study of Intestinal Diseases. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 9,432 Views
  • 106 Download
  • 37 Web of Science
  • 39 Crossref
Full Article

Download PDF Download PDF

  • Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical response ranging from 61% to 96%. However, the long-term prognosis of patients treated with tacrolimus is disappointing, and almost 50% of patients eventually underwent colectomy in long-term follow-up. Tacrolimus can achieve mucosal healing in 40-50% of patients, and this is associated with a favorable long-term prognosis. Anti-tumor necrosis factor (TNF)-α antibodies are another therapeutic option in corticosteroid-refractory patients. A prospective head-to-head comparative study of tacrolimus and infliximab is currently being performed to determine which treatment is more effective in corticosteroid-refractory patients. Several retrospective studies have demonstrated that switching between tacrolimus and anti-TNF-α antibody therapy was effective in patients who were refractory to one of the treatments. Most adverse events of tacrolimus are mild; however, opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during treatment. Several issues on tacrolimus treatment in UC patients remain unsolved (e.g., use of tacrolimus as remission maintenance therapy). Further controlled studies are needed to optimize the use of tacrolimus for the treatment of UC.
  • Keywords: Tacrolimus; Colitis, ulcerative; Cyclosporine; Calcineurin inhibitors
Ulcerative colitis (UC) is a chronic disease with a relapse-remitting course. Corticosteroids are the first choice in patients with moderate-to-severe disease activity. Although corticosteroids are an effective treatment option, approximately 40% of patients are resistant to or dependent on corticosteroids.
The treatment of corticosteroid-refractory UC is challenging, and colectomy is often indicated in these patients. Cyclosporine, a calcineurin inhibitor, has been used as a salvage therapy in corticosteroid-refractory patients. Lichtiger et al. reported a randomized controlled trial on the use of cyclosporine in acute severe UC.1 In this trial, 20 corticosteroid-refractory severe UC patients were randomly assigned to receive intravenous cyclosporine infusion at 4 mg/kg daily or placebo. The response rate at 7 days was 82% (9/11) in the cyclosporine group compared to 0% (0/9) in the placebo group. Intravenous cyclosporine is usually followed by oral cyclosporine, but intestinal absorption of cyclosporine is poor and unstable, and therefore, it is difficult to achieve optimal trough levels with oral cyclosporine.
Tacrolimus is a macrolide antibiotic, isolated from the soil bacterium Streptomyces tsukubaensis. It possesses potent immunosuppressive properties and has been used to prevent organ rejection after allogeneic organ transplantation or graft-versus-host disease after hematopoietic stem cell transplantation. The absorption of tacrolimus through the intestine is much better than that of cyclosporine. Considering these properties of tacrolimus, it is commonly used for the treatment of corticosteroid-refractory UC instead of cyclosporine. In Japan, tacrolimus was approved for clinical use in corticosteroid-refractory UC patients in 2010 and has been incorporated in the management of refractory UC. Here, we review the literature on the use of tacrolimus in UC patients.
Tacrolimus mainly exerts its immunosuppressive action by inhibiting T-cell activation and proliferation. Upon T-cell receptor activation by antigen-presenting cells, intracellular calcium concentrations increase, leading to activation of calcineurin, a calcium and calmodulin-dependent phosphatase. The transcription factor, nuclear factor of activated T-cells (NFAT) is dephosphorylated by calcineurin, and then, it moves to the nucleus and induces transcription of interleukin-2 and other related genes. interleukin-2 is essential for T-cell activation and proliferation. Tacrolimus binds to the immunophilin FK binding protein (FKBP) and forms a complex, which binds to calcineurin and inhibits its activity. The immunosuppressive properties of tacrolimus have been reported to be 100 times greater than those of cyclosporine both in vivo and in vitro.23
The first case series to assess the efficacy of tacrolimus for IBD was reported in 1998.4 This study included 11 corticosteroid-refractory patients (6 with UC, 2 with indeterminate colitis, 2 with CD, and 1 with pouchitis). All patients were treated with intravenous tacrolimus for 7-10 days, followed by oral tacrolimus treatment. Of the 11 patients, 7 (63.6%) achieved remission.
The first randomized double-blind controlled trial on the use of oral tacrolimus in UC patients was reported by Ogata et al. in 2006.5 In this study, 60 corticosteroid-refractory UC patients were randomly assigned to receive oral tacrolimus at high serum trough (10-15 ng/mL; n=19) or low serum trough (5-10 ng/mL; n=21) levels, or placebo (n=20). At 2 weeks after treatment, the clinical response rates were 68.4% and 38.1% in the high trough and low trough groups, respectively, and 10.0% in the placebo group. Ogata et al. further examined the efficacy of oral tacrolimus in a large randomized controlled trial that included 62 patients with corticosteroid-refractory, moderate-to-severe UC.6 In this study, the serum trough levels were fixed at 10-15 ng/mL in the tacrolimus group. A result similar to that of the first study was obtained, with clinical response rates of 50.0% in the tacrolimus group and 13.3% in the placebo group. Presently, these studies are the only controlled trials on the efficacy of tacrolimus in UC patients.
Many retrospective cohort studies have examined the efficacy of tacrolimus in UC patients in real-world settings456789101112131415161718192021 (Table 1). The largest study was reported from Germany, and it included 130 patients from 3 institutions.15 In this study, clinical remission was achieved in 94 patients (72%). Furthermore, the authors reported that concomitant use of thiopurine significantly increased the rate of remission. Miyoshi et al. reported 51 patients who were treated with oral tacrolimus. In this study, the clinical response rate at 3 months after treatment was 62.7% (32/53; 20 patients (39.2%) in remission, 12 patients (23.5%) with improvement).22
Several retrospective studies have shown the efficacy of tacrolimus in pediatric patients. A study that included 46 pediatric patients with corticosteroid-refractory colitis showed that 93% of patients avoided immediate colectomy with tacrolimus.2324 Ziring et al. reported the outcomes of 18 consecutive pediatric patients who were treated with oral tacrolimus. Of the 18 patients, 17 (94.4%) responded to treatment.25
Taken together, these findings suggest that tacrolimus is an effective treatment for remission induction in corticosteroid-refractory UC patients, although evidence from controlled studies is limited.
Despite the high response rates in remission induction with tacrolimus, long-term prognosis after tacrolimus treatment is disappointing. Miyoshi et al. analyzed 51 patients who were treated with tacrolimus and reported that the relapse-free survival rates were 73.0% at 6 months, 49.9% at 1 year, and 37.8% at 2 years after treatment.22 Additionally, a retrospective study from 3 French referral centers demonstrated that only 27% of patients had clinical remission at 54 weeks after treatment.26 Furthermore, the rates of long-term colectomy-free survival have been reported to be 56.5% at 43.8 months,10 59.3% at 2 years,16 and 62.3% at 65 months after treatment.12 These findings demonstrate that immediate colectomy may be avoided with tacrolimus; however, about 50.0% of patients eventually required colectomy in long-term follow-up.
A few uncontrolled studies suggested the effect of tacrolimus on remission maintenance. A study by Baumgart et al. assessed the long-term efficacy of oral low-dose tacrolimus in 40 UC patients. Of these 40 patients, 31 (77.5%) maintained remission during a mean treatment duration of 25.2 months at serum trough levels of 4-8 ng/mL.10 A retrospective analysis by Yamamoto et al. showed that the long-term relapse-free survival rates of patients administered tacrolimus as remission induction therapy (n=24) were comparable to those of patients administered thiopurine (n=34).27 These findings suggest that tacrolimus can be used as remission maintenance therapy. Randomized controlled studies are necessary to show the effects of long-term tacrolimus administration as remission maintenance therapy in UC patients. Additionally, studies to determine the optimal duration and trough levels for remission maintenance are required.
Mucosal healing has been an emerging therapeutic target in UC treatment. In the study by Ogata et al. in 2012, the rate of mucosal healing at 12 weeks after treatment was 43.8% (14/32) in the tacrolimus group and 13.3% (4/30) in the placebo group.6 Miyoshi et al. reported the endoscopic results of 36 patients who received oral tacrolimus treatment and underwent colonoscopy after 3 months of treatment. Of these 36 patients, 12 (33.3%) and 10 (27.8%) showed Mayo endoscopic scores of 0 and 1, respectively.22 Furthermore, patients with a Mayo endoscopic score of 0 or 1 had a significantly better medium-to-long term prognosis compared to that in those with a score of 3 or 4. Additionally, Ikeya et al. reported that the rate of mucosal healing was 43.8% (14/32) in patients treated with tacrolimus and that mucosal healing was associated with a favorable prognosis.21 These findings confirm that mucosal healing can be achieved with tacrolimus and may be used as a therapeutic target of this treatment.
Anti-TNF-α antibody therapy is an option for the treatment of corticosteroid-refractory UC.2829 Thus far, no direct comparative studies have assessed the efficacy of tacrolimus and anti-TNF-α antibody therapy in UC patients. A randomized, prospective head-to-head comparative study of tacrolimus and infliximab in corticosteroid-refractory UC patients is being performed in Japan.
A recent randomized controlled study demonstrated that infliximab and cyclosporine, another calcineurin inhibitor, were equally effective for remission induction in corticosteroid-refractory acute severe UC patients.30 Additionally, several retrospective studies have shown a similar efficacy between infliximab and cyclosporine for remission induction; however, long-term prognosis was more favorable in patients treated with infliximab than in those treated with cyclosporine.31323334 A recent retrospective study assessed short-term outcomes in patients with severe UC treated with tacrolimus (n=22) or infliximab (n=7).35 The rates of clinical remission were 63.6% and 71.4% in the tacrolimus and infliximab groups, respectively.
These findings suggest that the therapeutic effect of calcineurin inhibitors is comparable to that of infliximab in terms of remission induction. However, the mechanisms of action of these drugs are completely different. Therefore, it is important to select an appropriate therapy in each patient. Additionally, the optimization of remission maintenance therapy is challenging after calcineurin inhibitor therapy.
Three studies have used infliximab as rescue therapy in patients who were refractory to tacrolimus, and the shortterm response rates were 25.0% (6/24),36 46.2% (6/13),37 and 50.0% (6/12) in these studies.38 Yamamoto et al. further showed that the rate of colectomy-free survival was 58.3% at 41.4 months after treatment.38 Conversely, Boschetti et al. evaluated the efficacy of tacrolimus in 30 patients who were refractory to anti-TNF-α antibody therapy.26 In this study, clinical response was observed in 21 patients (70%) at 4 weeks after treatment, with 14 patients (47%) in clinical remission, and 8 patients (27%) maintained clinical remission at 52 weeks after treatment. These findings suggest that switching between tacrolimus and anti-TNF-α antibody therapy may be an effective therapeutic option in selected patients. However, evidence on long-term prognosis is scarce.
Attention should be paid to the risk of opportunistic infections when switching between 2 immunosuppressive agents.39 Additionally, there is a concern that the use of multiple immunosuppressive agents increases perioperative complications. Saito et al. reported that the frequency of postoperative complications did not increase in patients who underwent colectomy after receiving multiple immunosuppressive agents compared to that in patients who underwent colectomy after receiving only 1 immunosuppressive agent.40 The benefits and risks should be carefully considered when switching between a calcineurin inhibitor and anti-TNF-α antibody therapy.
The therapeutic effect of tacrolimus appears to depend on the trough level. In the study by Ogata et al. in 2006, the clinical response rate was higher in the high trough (10-15 ng/mL) group than in the low trough (5-10 ng/mL) group.5 Additionally, the study by Ogata et al. in 2012 showed that continuation of tacrolimus at a low trough level (5-10 ng/mL) until 12 weeks increased the rate of mucosal healing from 66.7% (14/21) to 85.7% (18/21) and that of clinical remission from 14.3% (3/21) to 28.6% (6/21).6 Based on these findings, the standard target trough level in Japan is 10-15 ng/mL for 2 weeks, followed by 5-10 ng/mL for 12 weeks. However, for long-term use of tacrolimus, the optimal trough level has not yet been determined.
Several factors affect the blood trough levels of tacrolimus. First, fasting affects the pharmacokinetics of tacrolimus. Cmax is almost 4 times higher in a fasting condition than in a fed condition.41 Second, genetic backgrounds can affect the blood trough levels of tacrolimus. Tacrolimus is metabolized predominantly by cytochrome P-450 (CYP) 3A4 and 3A5 enzymes, and is a substrate for the drug efflux pump Pglycoprotein encoded by the ABCB1 gene. A German study reported that the short-term response to tacrolimus was associated with homozygous variants for 1 of the 3 ABCB1 alleles, but not with CYP3A5 polymorphisms.14 Interestingly, a Japanese study reported opposite results. Hirai et al. examined the expression of CYP3A5 in 45 patients treated with tacrolimus.19 Of these 45 patients, 24 (53.3%) were CYP3A5 expressers and 21 (46.7%) were non-expressers. The trough levels at 2-5 days after treatment were significantly higher in the CYP3A5 expressers than in the non-expressers. This rapid increase in trough levels was associated with a higher rate of remission in the non-expressers (47.6%) than in the expressers (16.7%). ABCB1 gene polymorphisms were not associated with trough levels. These findings suggest a genetic difference between Asian and Caucasian populations in tacrolimus metabolism.
Both oral and intravenous formulas are available in tacrolimus treatment. The oral formula is often used for the treatment of UC, because tacrolimus is efficiently absorbed from the intestine.
Fellermann et al. compared intravenous administration of tacrolimus with oral administration in 38 patients with colitis (33 with UC and 5 with indeterminate colitis).7 In this study, tacrolimus was administered intravenously at a dose of 0.01-0.02 mg/kg in 18 patients for up to 14 days, followed by oral administration. Additionally, it was administered orally at a dose of 0.1-0.2 mg/kg in 20 patients. The efficacy was similar between the intravenous and oral groups in terms of the rates of response, remission, and colectomy. Additionally, blood tacrolimus levels were comparable between the 2 groups. In our experience, response rates are similar in patients treated with tacrolimus intravenously and those treated orally. However, target blood levels can be achieved within a few days with intravenous infusion, while it takes 4-5 days to reach target blood trough levels with oral administration (unpublished data). Thus, the therapeutic response can be determined earlier in intravenously treated patients than in orally treated patients, and this earlier decision can be critical in severely ill patients.
Rectal administration of tacrolimus may be effective in patients with left-sided colitis or proctitis, because tacrolimus ointment is used to treat atopic dermatitis. A study examined the efficacy of tacrolimus enema or suppository in distal colitis.42 The enema and suppository contained 2-4 mg and 2 mg of tacrolimus, respectively. After treatment for 4 weeks, 13 of 19 patients (68.4%) showed clinical improvement. Additionally, a small prospective study demonstrated that 6 of 8 patients with refractory distal colitis achieved remission with rectal tacrolimus administration.43 Uchino et al. used tacrolimus enema in 10 patients with antibiotic-refractory pouchitis.44 In this study, clinical symptoms improved in 9 patients (90.0%) after 8 weeks of treatment. Based on these findings, rectal tacrolimus treatment may be effective and should be examined in future randomized controlled studies.
A systematic review examining tacrolimus use in UC patients reported that the most frequently observed adverse events were neurotoxicity, including tremor and headache, followed by gastrointestinal disorders, nephrotoxicity, and metabolic disorders.45 Most of the adverse events were mild, and could be attenuated by reducing the dose of tacrolimus. Opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during tacrolimus treatment.46 Prophylaxis for pneumocystis pneumonia and its close monitoring should be considered in patients treated with tacrolimus.
Safety data on the long-term administration of tacrolimus in UC patients are limited. Baumgart et al. reported on 53 IBD patients (40 with UC, 11 with CD, and 2 with pouchitis) who were treated with tacrolimus for a mean of 25.2 months.10 In this study, the most common adverse events were tremor and paresthesia (n=5, 9.4%), followed by a temporal rise in serum creatinine levels (n=4, 7.6%). Nephrotoxicity may be a limiting factor for the long-term use of tacrolimus.
Tacrolimus shows excellent efficacy for remission induction in corticosteroid-refractory UC patients. However, several questions remain unanswered: (1) Can tacrolimus be used as maintenance therapy? (2) What is the optimal trough level for long-term use? (3) What is the optimal administration route? (4) How to determine whether to administer tacrolimus or anti-TNF-α antibody therapy? (5) Is combination therapy of low-dose tacrolimus and infliximab, which has been reported to be effective in rheumatoid arthritis patients, feasible in UC patients? More controlled studies are needed to answer these clinical questions regarding tacrolimus and optimize its use in the treatment of UC. Furthermore, the identification of predictive factors or development of biomarkers to predict therapeutic responses to tacrolimus is needed. Tacrolimus is used primarily in Japan among the Asian countries,47 and it can become an indispensable treatment option for corticosteroid-refractory UC globally with further optimization of its use.

Financial support: This study was supported in part by Grants-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology; Health and Labour, Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan.

Conflict of interest: None.

  • 1. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841–1845.PMID: 8196726.ArticlePubMed
  • 2. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256–1265.PMID: 2445722.ArticlePubMed
  • 3. Hirano T, Akashi T, Kido T, Oka K, Shiratori T, Miyaoka M. Immunosuppressant pharmacodynamics on peripheral-blood mononuclear cells from patients with ulcerative colitis. Int Immunopharmacol 2002;2:1055–1063.PMID: 12349943.ArticlePubMed
  • 4. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860–1866.PMID: 9772045.ArticlePubMed
  • 5. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55:1255–1262.PMID: 16484504.ArticlePubMedPMC
  • 6. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012;18:803–808.PMID: 21887732.ArticlePubMed
  • 7. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002;8:317–324.PMID: 12479646.ArticlePubMed
  • 8. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:415–423.PMID: 12940927.ArticlePubMed
  • 9. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1273–1281.PMID: 12755840.ArticlePubMed
  • 10. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 2006;101:1048–1056.PMID: 16573777.ArticlePubMed
  • 11. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:129–134.PMID: 17206694.ArticlePubMed
  • 12. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008;28:589–597.PMID: 18549460.ArticlePubMed
  • 13. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008;14:7–12.PMID: 17879277.ArticlePubMed
  • 14. Herrlinger KR, Koc H, Winter S, et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther 2011;89:422–428.PMID: 21289623.ArticlePubMed
  • 15. Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther 2013;37:129–136.PMID: 23121200.ArticlePubMed
  • 16. Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis 2013;19:1490–1498.PMID: 23615528.ArticlePubMed
  • 17. Mizoshita T, Tanida S, Tsukamoto H, et al. Colon mucosa exhibits loss of ectopic MUC5AC expression in patients with ulcerative colitis treated with oral tacrolimus. ISRN Gastroenterol 2013;2013:304894PMID: 23691335.ArticlePubMedPMCPDF
  • 18. Landy J, Wahed M, Peake ST, et al. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres. J Crohns Colitis 2013;7:e516–e521.PMID: 23623737.ArticlePubMedPDF
  • 19. Hirai F, Takatsu N, Yano Y, et al. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. J Gastroenterol Hepatol 2014;29:60–66.PMID: 24033383.Article
  • 20. Kawakami K, Inoue T, Murano M, et al. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015;21:1880–1886.PMID: 25684955.ArticlePubMedPMC
  • 21. Ikeya K, Sugimoto K, Kawasaki S, et al. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis 2015;47:365–371.PMID: 25682993.ArticlePubMed
  • 22. Miyoshi J, Matsuoka K, Inoue N, et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis 2013;7:e609–e614.PMID: 23680174.ArticlePubMedPDF
  • 23. Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011;17:22–29.PMID: 20722055.ArticlePubMed
  • 24. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794–799.PMID: 11113835.ArticlePubMed
  • 25. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007;45:306–311.PMID: 17873742.ArticlePubMed
  • 26. Boschetti G, Nancey S, Moussata D, et al. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. Dig Liver Dis 2014;46:875–880.PMID: 25023007.ArticlePubMed
  • 27. Yamamoto S, Nakase H, Matsuura M, Masuda S, Inui K, Chiba T. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol 2011;45:526–530.PMID: 21336140.ArticlePubMed
  • 28. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.PMID: 16339095.ArticlePubMed
  • 29. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780–787.PMID: 21209123.ArticlePubMed
  • 30. Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909–1915.PMID: 23063316.ArticlePubMed
  • 31. Naves JE, Llaó J, Ruiz-Cerulla A, et al. Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. Inflamm Bowel Dis 2014;20:1375–1381.PMID: 25046008.ArticlePubMed
  • 32. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013;38:294–302.PMID: 23786158.ArticlePubMed
  • 33. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol 2012;27:487–492.PMID: 22098019.ArticlePubMed
  • 34. Mocciaro F, Renna S, Orlando A, et al. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 2012;6:681–686.PMID: 22398101.ArticlePubMedPDF
  • 35. Minami N, Yoshino T, Matsuura M, et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastro 2010;PMID: 10.1136/bmjgast-2014-000021. Published online 20 February 2015.Article
  • 36. Herrlinger KR, Barthel DN, Schmidt KJ, et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther 2010;31:1036–1041.PMID: 20175769.ArticlePubMed
  • 37. Tsukamoto H, Tanida S, Mizoshita T, et al. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. Eur J Gastroenterol Hepatol 2013;25:714–718.PMID: 23411870.ArticlePubMed
  • 38. Yamamoto S, Nakase H, Matsuura M, et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol 2010;25:886–891.PMID: 20546441.ArticlePubMed
  • 39. Leblanc S, Allez M, Seksik P, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. Am J Gastroenterol 2011;106:771–777.PMID: 21386832.ArticlePubMedPDF
  • 40. Saito E, Nagahori M, Fujii T, Ohtsuka K, Watanabe M. Efficacy of salvage therapy and its effect on operative outcomes in patients with ulcerative colitis. Digestion 2014;89:55–60.PMID: 24458114.ArticlePubMed
  • 41. Lainesse A, Hussain S, Monif T, et al. Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. Arzneimittelforschung 2008;58:242–247.PMID: 18589558.ArticlePubMedPDF
  • 42. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009;15:193–198.PMID: 18825773.ArticlePubMed
  • 43. Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214–1220.PMID: 18761706.ArticlePubMed
  • 44. Uchino M, Ikeuchi H, Matsuoka H, et al. Topical tacrolimus therapy for antibiotic-refractory pouchitis. Dis Colon Rectum 2013;56:1166–1173.PMID: 24022534.ArticlePubMed
  • 45. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006;51:1833–1840.PMID: 16964541.ArticlePubMed
  • 46. Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis-a need for prophylaxis. J Crohns Colitis 2010;4:606–609.PMID: 21122569.ArticlePubMedPDF
  • 47. Hida N, Nakamura S, Hahm KB, et al. A questionnaire-based survey on the diagnosis and management of inflammatory bowel disease in East Asian countries in 2012. Digestion 2014;89:88–103.PMID: 24458117.ArticlePubMed
Table 1

Summary of Tacrolimus Treatment in Adult UC Patients

ir-13-219-i001.jpg
Reference Study design N Administration route Treatment duration Observation period Response Remission Colectomy Initial daily dose Target trough level
Fellermann et al. (1998)4 Retro. cohort 6 i.v. → oral 0.25-16 mo - 0 (0.0) 4 (66.7) 2 (33.3) 0.01-0.02 mg/kg for i.v. -
0.1-0.2 mg/kg for oral
Fellermann et al. (2002)7 Retro. cohort 38 (incl. 5 IC) i.v. → oral (n=18) 7.6 mo* 16.2 mo* 10 (26.3) at 3 mo 13 (34.2) at 3 mo 13 (34.2) 0.01-0.02 mg/kg for i.v. -
oral (n=20) 0.1-0.2 mg/kg for oral
Hogenauer et al. (2003)8 Retro. cohort 9 oral 15 wk* 21 mo* 2 (22.2) at 12 wk 6 (66.7) at 12 wk 3 (33.3) 0.15mg/kg 10-20 ng/mL
Baumgart et al. (2003)9 Retro. cohort 23 oral 12 mo† 18.4 mo† 5 (21.7) 17 (73.9) 3 (13.0) 0.1 mg/kg 4-6 ng/mL
Ogata et al. (2006)5 RCT 19 in HT oral 2 wk 2 wk 13 (68.4) in HT 0 (0.0) 0 (0.0) 0.05 mg/kg 10-15 ng/mL in HT
21 in LT 8 (38.1) in LT 5-10 ng/mL in LT
Baumgart et al. (2006)10 Retro. cohort 40 oral 25.2 mo* 39 mo* 13 (32.5) at 4 wk 18 (45.0) at 4 wk 9 (22.5) 0.1 mg/kg 4-8 ng/mL
Ng et al. (2007)11 Retro. cohort 6 oral 5 mo† 8 mo† 1 (16.7) at 4 wk 3 (50.0) at 4 wk - - -
Yamamoto et al. (2008)12 Retro. cohort 27 oral 11 mo† 17.5 mo† 2 (7.4) at 4 wk 19 (70.4) at 4 wk 7 (26.9) 0.1 mg/kg 10-15 ng/mL → 5-10 ng/mL
Benson et al. (2008)13 Retro. cohort 32 oral 29 wk* 92 wk* 22 (68.8) 3 (9.3) 12 (37.5) 0.2 mg/kg 10-12 ng/mL
Herrlinger et al. (2011)14 Retro. cohort 84 oral 6 wk 6 wk 12 (14.3) 51 (60.7) 25 (29.8) 0.1-0.2 mg/kg 10 ng/mL
Ogata et al. (2012)6 RCT 32 oral 2 wk 2 wk 13 (40.6) 3 (9.3) 0 (0.0) 2-5 mg/day 10-15 ng/mL
Schmidt et al. (2013)15 Retro. cohort 130 oral 12 wk 12 wk - 94 (72.3) 18 (13.8) 0.1 mg/kg -
Thin et al. (2013)16 Retro. cohort 24 oral 11 mo* 1 yr 12 (50.0) at 3 mo, 4 (16.7) at 1 yr 8 (33.3) at 3 mo 4 (16.7) at 1 yr 16 (66.7) 0.1 mg/kg 8-12 ng/mL
Mizoshita et al. (2013)17 Retro. cohort 26 oral 12 wk 12 wk 14 (53.8) 4 (15.4) - - 10-15 ng/mL → 5-10 ng/mL
Landy et al. (2013)18 Retro. cohort 25 oral 9 mo† 27 mo† 13 (52.0) at 6 mo 11 (44.0) at 6 mo 8 (32.0) 0.1 mg/kg 5-10 ng/mL
Hirai et al. (2014)19 Retro. cohort 45 oral 4 wk 4 wk - 14 (31.1) 4 (8.9) 0.1 mg/kg 10-15 ng/mL
Kawakami et al. (2015)20 Prospective observational cohort 49 oral 4 wk 4 wk 7 (14.3) 37 (75.5) 3 (6.1) 0.1 mg/kg 10-15 ng/mL → 5-10 ng/mL
Ikeya et al. (2015)21 Retro. cohort 44 oral 51.7 wk* 12 wk 9 (28.1) at 12 wk 29 (65.9) at 12 wk 7 (15.9) 0.1 mg/kg 10-15 ng/mL → 5-10 ng/mL

Values are presented as n (%).

*mean, †median.

Retro, retrospective; i.v., intravenous; incl., including; IC, indeterminate colitis; RCT, randomized controlled trial; HT, high trough; LT, low trough.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study
      Naoki Oshima, Sakiko Hiraoka, Ryohei Hayashi, Sakuma Takahashi, Manabu Ishii, Shinichi Hashimoto, Kazuo Yashima, Shoko Igawa, Toshihiro Inokuchi, Yoshitaka Ueno, Tomoki Inaba, Hiroshi Matsumoto, Kousaku Kawashima, Taro Takami, Hajime Isomoto, Akiko Shiota
      Inflammatory Bowel Diseases.2024; 30(7): 1087.     CrossRef
    • Exploring the therapeutic potential of Anastatica hierochuntica essential oil in DSS-induced colitis
      Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Mohammed Alqudah, Muna Oqal, Rawan Abudalo, Shtaywy S. Abdalla
      Inflammopharmacology.2024; 32(3): 2035.     CrossRef
    • Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
      Javier P Gisbert, María José García, María Chaparro
      Journal of Crohn's and Colitis.2023; 17(6): 972.     CrossRef
    • Gastrointestinal tract and viral pathogens
      Gowthami Sai Kogilathota Jagirdhar, Yashwitha Sai Pulakurthi, Himaja Dutt Chigurupati, Salim Surani
      World Journal of Virology.2023; 12(3): 136.     CrossRef
    • Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection
      Ting Xue, Xiaomei Kong, Liang Ma
      Journal of Fungi.2023; 9(8): 812.     CrossRef
    • Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease
      Florian Uellendahl-Werth, Carlo Maj, Oleg Borisov, Simonas Juzenas, Eike Matthias Wacker, Isabella Friis Jørgensen, Tim Alexander Steiert, Saptarshi Bej, Peter Krawitz, Per Hoffmann, Christoph Schramm, Olaf Wolkenhauer, Karina Banasik, Søren Brunak, Stefa
      Communications Biology.2022;[Epub]     CrossRef
    • Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis
      Jiaxing Zhao, Bing Zhang, Qing Mao, Kunqi Ping, Peng Zhang, Fengwei Lin, Dan Liu, Yao Feng, Ming Sun, Yan Zhang, Qiu Hua Li, Tingjian Zhang, Yanhua Mou, Shaojie Wang
      Journal of Medicinal Chemistry.2022; 65(6): 4926.     CrossRef
    • Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis
      Morris Gordon, Vassiliki Sinopoulou, Anthony K Akobeng, Mirela Pana, Rehab Gasiea, Gordon William Moran
      Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
    • Combination tacrolimus and ustekinumab therapy is effective in inducing clinical, biochemical and endoscopic remission in refractory moderate to severe ulcerative colitis
      Rachit Gupta, Julien D. Schulberg, Ola Niewiadomski, Emily K. Wright
      Autoimmunity Reviews.2022; 21(7): 103115.     CrossRef
    • Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis
      Sujaata Dwadasi, Maryam Zafer, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D Cohen, Joel Pekow, David T Rubin, Atsushi Sakuraba, Dejan Micic
      Inflammatory Bowel Diseases.2021; 27(10): 1620.     CrossRef
    • Treatment of acute severe ulcerative colitis
      Jun-Rong Li, Fang-Mei Ling, Yi-Dong Chen, Ming-Yang Xu, Liang-Ru Zhu
      World Chinese Journal of Digestology.2021; 29(2): 87.     CrossRef
    • Role of Topical Tacrolimus in the Management of Proctitis, Perianal Manifestations in Crohn's Disease, and Chronic Pouchitis: A Systematic Review
      George Salem, Kai Ding, Atsushi Sakuraba, Russell Cohen
      Journal of Investigative Medicine.2021; 69(4): 796.     CrossRef
    • The Optimal Dose of Tacrolimus in Combination Therapy with an Anti-TNFα Antibody in a Mouse Colitis Model
      Yuki Murakami, Mikihiro Fujiya, Hiroaki Konishi, Shotaro Isozaki, Yuya Sugiyama, Yu Kobayashi, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura
      Biological and Pharmaceutical Bulletin.2021; 44(4): 564.     CrossRef
    • Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis
      Roberto Manzini, Marlene Schwarzfischer, Kirstin Atrott, Andrea Laimbacher, Silvia Lang, Marcin Wawrzyniak, Andreas Rickenbacher, Matthias Turina, Petr Hruz, Donata Lissner, Britta Siegmund, Gerhard Rogler, Michael Scharl, Marianne R Spalinger
      Inflammatory Bowel Diseases.2021; 27(12): 1986.     CrossRef
    • The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
      Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
      PLOS ONE.2021; 16(4): e0250597.     CrossRef
    • De Novo Inflammatory Bowel Disease Rarely Occurs During Posttransplant Immunosuppression
      Jiayun M Fang, Laura Lamps, Amoah Yeboah-Korang, Jerome Cheng, Maria Westerhoff
      American Journal of Clinical Pathology.2021; 156(6): 1113.     CrossRef
    • Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis
      Sara Hone Lopez, Gursah Kats-Ugurlu, Remco J. Renken, Henk J. Buikema, Marco R. de Groot, Marijn C. Visschedijk, Gerard Dijkstra, Mathilde Jalving, Jacco J. de Haan
      Virchows Archiv.2021; 479(6): 1119.     CrossRef
    • Protective effects of selenium in tacrolimus-induced lung toxicity: potential role of heme oxygenase 1
      Salwa Abdel-Tawab Ibrahim, Nashwa Fathy Eltahawy, Ahlam Mohamed Abdalla, Hanaa Mohamed Khalaf
      Canadian Journal of Physiology and Pharmacology.2021; 99(10): 1069.     CrossRef
    • Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review
      Biyu Wu, Jinglu Tong, Zhihua Ran
      Inflammatory Bowel Diseases.2020; 26(1): 24.     CrossRef
    • Simple water‐based tacrolimus enemas for refractory proctitis
      Sasha R. Fehily, Felicity C. Martin, Michael A. Kamm
      JGH Open.2020; 4(4): 561.     CrossRef
    • Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody
      Miki Kojima, Satoru Oji, Satoru Tanaka, Shoko Izaki, Baku Hashimoto, Hikoaki Fukaura, Kyoichi Nomura
      Multiple Sclerosis and Related Disorders.2020; 39: 101907.     CrossRef
    • Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
      Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara
      Journal of Clinical Medicine.2020; 9(6): 1771.     CrossRef
    • Inflammatory Bowel Disease – Non-biological treatment
      Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
      Pharmacological Research.2020; 160: 105075.     CrossRef
    • Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis
      Peng Yu, Chuxin Ke, Jiaxin Guo, Xiuling Zhang, Bailiang Li
      Frontiers in Immunology.2020;[Epub]     CrossRef
    • 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease
      Iria Seoane-Viaño, Noemí Gómez-Lado, Héctor Lázare-Iglesias, Xurxo García-Otero, José Ramón Antúnez-López, Álvaro Ruibal, Juan Jesús Varela-Correa, Pablo Aguiar, Abdul W. Basit, Francisco J. Otero-Espinar, Miguel González-Barcia, Alvaro Goyanes, Asteria L
      Biomedicines.2020; 8(12): 563.     CrossRef
    • A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis
      Kiyonori Kobayashi, Yasuo Suzuki, Kenji Watanabe, Kazunori Oda, Miyuki Mukae, Akihiro Yamada, Hirokazu Yamagami, Akira Nishimura, Hiroyuki Okamoto
      The Journal of Clinical Pharmacology.2019; 59(2): 271.     CrossRef
    • Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease
      Britt Christensen, Peter R. Gibson, Dejan Micic, Ruben J. Colman, Sarah R. Goeppinger, Olufemi Kassim, Andres Yarur, Christopher R. Weber, Russell D. Cohen, David T. Rubin
      Clinical Gastroenterology and Hepatology.2019; 17(3): 486.     CrossRef
    • The protective role of phloretin against dextran sulfate sodium-induced ulcerative colitis in mice
      Zecai Zhang, Shan Li, Hongyang Cao, Peng Shen, Jiuxi Liu, Yunhe Fu, Yongguo Cao, Naisheng Zhang
      Food & Function.2019; 10(1): 422.     CrossRef
    • Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction
      Yu Nishida, Shuhei Hosomi, Hirokazu Yamagami, Naoko Sugita, Shigehiro Itani, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara, Emiko Mizoguchi
      PLOS ONE.2019; 14(3): e0213505.     CrossRef
    • Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis
      Peter Hoffmann, Cyrill Wehling, Johannes Krisam, Jan Pfeiffenberger, Nina Belling, Annika Gauss
      World Journal of Gastroenterology.2019; 25(13): 1603.     CrossRef
    • Advances in research of tacrolimus for treatment of inflammatory bowel disease
      Jing-Jing Wang, Yi-Hong Fan
      World Chinese Journal of Digestology.2019; 27(13): 842.     CrossRef
    • Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling
      Huining Fan, Wei Chen, Jinshui Zhu, Jing Zhang, Shiqiao Peng
      International Immunopharmacology.2019; 76: 105909.     CrossRef
    • Pharmacotherapy of ulcerative colitis – current status and emerging trends
      Hilal Ahmad, Vijay L. Kumar
      Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581.     CrossRef
    • Updated treatment strategies for intestinal Behçet’s disease
      Yong Eun Park, Jae Hee Cheon
      The Korean Journal of Internal Medicine.2018; 33(1): 1.     CrossRef
    • Tacrolimus: An updated review on delivering strategies for multifarious diseases
      Divya Dheer, Jyoti, Prem N. Gupta, Ravi Shankar
      European Journal of Pharmaceutical Sciences.2018; 114: 217.     CrossRef
    • Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis
      Yi-Juan Liu, Hua Fan, Wei-Wei Zhen, Xing Yu, Jin-Tong Chen, Cheng-Dang Wang
      Medicine.2018; 97(32): e11440.     CrossRef
    • Long-lasting Immunosuppressive Effects of tacrolimus-loaded Micelle NK61060 in Preclinical Arthritis and Colitis Models
      Takamichi Sato, Junpei Konno, Akihiro Sekiguchi, Nao Yoneki, Kana Kawano, Tomohiro Hayashi, Yukina Ogawa, Aya Kikitsu, Takashi Aijima, Kazuhisa Hara, Shintaro Hara, Hitomi Hayashi, Kimiko Fuchigami, Naoko Igo, Yuki Takashima, Yuki Kobayashi, Masayuki Mori
      Therapeutic Delivery.2018; 9(10): 711.     CrossRef
    • In Vivo Study of the Efficacy of the Essential Oil of Zanthoxylum bungeanum Pericarp in Dextran Sulfate Sodium-Induced Murine Experimental Colitis
      Zecai Zhang, Peng Shen, Jiuxi Liu, Cong Gu, Xiaojie Lu, Yanxin Li, Yongguo Cao, Bo Liu, Yunhe Fu, Naisheng Zhang
      Journal of Agricultural and Food Chemistry.2017; 65(16): 3311.     CrossRef
    • Significant contribution of TRPC6 channel-mediated Ca2+ influx to the pathogenesis of Crohn’s disease fibrotic stenosis
      Lin Hai Kurahara, Keizo Hiraishi, Miho Sumiyoshi, Mayumi Doi, Yaopeng Hu, Kunihiko Aoyagi, Yuwen Jian, Ryuji Inoue
      Journal of Smooth Muscle Research.2016; 52: 78.     CrossRef

    • PubReader PubReader
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Tacrolimus for the Treatment of Ulcerative Colitis
      Intest Res. 2015;13(3):219-226.   Published online June 9, 2015
      DOI: https://doi.org/10.5217/ir.2015.13.3.219
      Close
    • XML DownloadXML Download
    Tacrolimus for the Treatment of Ulcerative Colitis
    Tacrolimus for the Treatment of Ulcerative Colitis

    Summary of Tacrolimus Treatment in Adult UC Patients

    ReferenceStudy designNAdministration routeTreatment durationObservation periodResponseRemissionColectomyInitial daily doseTarget trough level
    Fellermann et al. (1998)4Retro. cohort6i.v. → oral0.25-16 mo-0 (0.0)4 (66.7)2 (33.3)0.01-0.02 mg/kg for i.v.-
    0.1-0.2 mg/kg for oral
    Fellermann et al. (2002)7Retro. cohort38 (incl. 5 IC)i.v. → oral (n=18)7.6 mo*16.2 mo*10 (26.3) at 3 mo13 (34.2) at 3 mo13 (34.2)0.01-0.02 mg/kg for i.v.-
    oral (n=20)0.1-0.2 mg/kg for oral
    Hogenauer et al. (2003)8Retro. cohort9oral15 wk*21 mo*2 (22.2) at 12 wk6 (66.7) at 12 wk3 (33.3)0.15mg/kg10-20 ng/mL
    Baumgart et al. (2003)9Retro. cohort23oral12 mo†18.4 mo†5 (21.7)17 (73.9)3 (13.0)0.1 mg/kg4-6 ng/mL
    Ogata et al. (2006)5RCT19 in HToral2 wk2 wk13 (68.4) in HT0 (0.0)0 (0.0)0.05 mg/kg10-15 ng/mL in HT
    21 in LT8 (38.1) in LT5-10 ng/mL in LT
    Baumgart et al. (2006)10Retro. cohort40oral25.2 mo*39 mo*13 (32.5) at 4 wk18 (45.0) at 4 wk9 (22.5)0.1 mg/kg4-8 ng/mL
    Ng et al. (2007)11Retro. cohort6oral5 mo†8 mo†1 (16.7) at 4 wk3 (50.0) at 4 wk---
    Yamamoto et al. (2008)12Retro. cohort27oral11 mo†17.5 mo†2 (7.4) at 4 wk19 (70.4) at 4 wk7 (26.9)0.1 mg/kg10-15 ng/mL → 5-10 ng/mL
    Benson et al. (2008)13Retro. cohort32oral29 wk*92 wk*22 (68.8)3 (9.3)12 (37.5)0.2 mg/kg10-12 ng/mL
    Herrlinger et al. (2011)14Retro. cohort84oral6 wk6 wk12 (14.3)51 (60.7)25 (29.8)0.1-0.2 mg/kg10 ng/mL
    Ogata et al. (2012)6RCT32oral2 wk2 wk13 (40.6)3 (9.3)0 (0.0)2-5 mg/day10-15 ng/mL
    Schmidt et al. (2013)15Retro. cohort130oral12 wk12 wk-94 (72.3)18 (13.8)0.1 mg/kg-
    Thin et al. (2013)16Retro. cohort24oral11 mo*1 yr12 (50.0) at 3 mo, 4 (16.7) at 1 yr8 (33.3) at 3 mo 4 (16.7) at 1 yr16 (66.7)0.1 mg/kg8-12 ng/mL
    Mizoshita et al. (2013)17Retro. cohort26oral12 wk12 wk14 (53.8)4 (15.4)--10-15 ng/mL → 5-10 ng/mL
    Landy et al. (2013)18Retro. cohort25oral9 mo†27 mo†13 (52.0) at 6 mo11 (44.0) at 6 mo8 (32.0)0.1 mg/kg5-10 ng/mL
    Hirai et al. (2014)19Retro. cohort45oral4 wk4 wk-14 (31.1)4 (8.9)0.1 mg/kg10-15 ng/mL
    Kawakami et al. (2015)20Prospective observational cohort49oral4 wk4 wk7 (14.3)37 (75.5)3 (6.1)0.1 mg/kg10-15 ng/mL → 5-10 ng/mL
    Ikeya et al. (2015)21Retro. cohort44oral51.7 wk*12 wk9 (28.1) at 12 wk29 (65.9) at 12 wk7 (15.9)0.1 mg/kg10-15 ng/mL → 5-10 ng/mL

    Values are presented as n (%).

    *mean, †median.

    Retro, retrospective; i.v., intravenous; incl., including; IC, indeterminate colitis; RCT, randomized controlled trial; HT, high trough; LT, low trough.
    Table 1 Summary of Tacrolimus Treatment in Adult UC Patients

    Values are presented as n (%).

    *mean, †median.

    Retro, retrospective; i.v., intravenous; incl., including; IC, indeterminate colitis; RCT, randomized controlled trial; HT, high trough; LT, low trough.

    Table 1

    Intest Res : Intestinal Research
    © Korean Association for the Study of Intestinal Diseases.
    Close layer
    TOP